Last reviewed · How we verify

Liposomal lidocaine

The Hospital for Sick Children · FDA-approved active Small molecule

Liposomal lidocaine is a local anesthetic encapsulated in liposomes that blocks sodium channels in nerve cell membranes to prevent pain signal transmission.

Liposomal lidocaine is a local anesthetic encapsulated in liposomes that blocks sodium channels in nerve cell membranes to prevent pain signal transmission. Used for Local anesthesia for pediatric procedures, Topical anesthesia for minor surgical procedures.

At a glance

Generic nameLiposomal lidocaine
Also known asMaxilene™, Maxilene
SponsorThe Hospital for Sick Children
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhaseFDA-approved

Mechanism of action

Lidocaine, a local anesthetic, works by inhibiting sodium influx through voltage-gated sodium channels in nerve fibers, thereby preventing depolarization and action potential propagation. The liposomal formulation encapsulates the lidocaine to improve drug delivery, reduce systemic toxicity, and potentially enhance local tissue penetration and duration of action.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: